Tweenvest Stocks

Cingulate Inc. (NasdaqCM: CING)

Health Care · Pharmaceuticals · US

$5.55

+9.04% today · +32.0% 1Y

Cingulate Inc. (NasdaqCM: CING) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $80.71M and employs 14 people.

Over the last twelve months the share price has gained 32.0%, trading between 3.16 and 11.89.

Tweenvest scores Cingulate Inc. across four factors: quality 21/100. Its strongest factor is quality.

CING price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$80.71M
Revenue (TTM)
P/E
EPS
-3.28
Dividend yield
Beta (5Y)
-0.91
52-week high
$11.89
52-week low
$3.16
Avg volume (3M)
Shares outstanding
14.54M
Employees
14
Next earnings

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Founded
2012
Listed since
Dec 8, 2021
Exchange
Nasdaq Capital Market
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.12T$1,255.40+0.88%
Johnson & JohnsonNYSE: JNJ$651.25B$270.24+1.07%
Merck & Co., Inc.NYSE: MRK$376.37B$152.55+2.39%
Roche Holding AGSWX: ROP$373.91BCHF375.60+1.02%
Novartis AGSWX: NOVN$302.17BCHF127.42+0.85%
AstraZeneca PLCLSE: AZN$258.76B£122.40+1.26%
Novo Nordisk A/SCPSE: NOVO B$207.84BDkr300.85+1.59%
Pfizer Inc.NYSE: PFE$159.99B$28.07+1.01%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.